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AbstrAct
Objectives
To describe the characteristics of children and 
adolescents affected by an outbreak of Kawasaki-like 
multisystem inflammatory syndrome and to evaluate 
a potential temporal association with severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection.
Design
Prospective observational study.
setting
General paediatric department of a university hospital 
in Paris, France.
ParticiPants
21 children and adolescents (aged ≤18 years) with 
features of Kawasaki disease who were admitted 
to hospital between 27 April and 11 May 2020 and 
followed up until discharge by 15 May 2020.
Main OutcOMe Measures
The primary outcomes were clinical and biological 
data, imaging and echocardiographic findings, 
treatment, and outcomes. Nasopharyngeal swabs 
were prospectively tested for SARS-CoV-2 using 
reverse transcription-polymerase chain reaction 
(RT-PCR) and blood samples were tested for IgG 
antibodies to the virus.
results
21 children and adolescents (median age 7.9 (range 
3.7-16.6) years) were admitted with features of 
Kawasaki disease over a 15 day period, with 12 
(57%) of African ancestry. 12 (57%) presented with 
Kawasaki disease shock syndrome and 16 (76%) 
with myocarditis. 17 (81%) required intensive 
care support. All 21 patients had noticeable 
gastrointestinal symptoms during the early stage of 
illness and high levels of inflammatory markers. 19 
(90%) had evidence of recent SARS-CoV-2 infection 
(positive RT-PCR result in 8/21, positive IgG antibody 
detection in 19/21). All 21 patients received 
intravenous immunoglobulin and 10 (48%) also 
received corticosteroids. The clinical outcome was 
favourable in all patients. Moderate coronary artery 
dilations were detected in 5 (24%) of the patients 
during hospital stay. By 15 May 2020, after 8 (5-17) 
days of hospital stay, all patients were discharged 
home.
cOnclusiOns
The ongoing outbreak of Kawasaki-like multisystem 
inflammatory syndrome among children and 
adolescents in the Paris area might be related 
to SARS-CoV-2. In this study an unusually high 
proportion of the affected children and adolescents 
had gastrointestinal symptoms, Kawasaki disease 
shock syndrome, and were of African ancestry.
Introduction
In children and adolescents, severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection is 
mostly responsible for mild respiratory symptoms, 
in contrast with severe forms reported in adults.1 2 
An association between the disease caused by SARS-
CoV-2, coronavirus disease 2019 (covid-19), and late 
manifestations of vasculitis has been increasingly 
suspected, especially in young asymptomatic patients, 
which might be due to post-viral immunological 
reactions.3 4
Kawasaki disease is the most common primary 
vasculitis in childhood, with medium and small sized 
arteries predominantly affected.5 The annual incidence 
of the disease is highest in Japan, with more than 300 
per 100 000 children aged 4 years or younger affected, 
compared with 25 per 100 000 children aged 5 years 
or younger in North America.6 7 One of the most severe 
complications of Kawasaki disease is coronary artery 
aneurysm.7 Kawasaki disease shock syndrome, a rare 
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WhAt Is AlreAdy knoWn on thIs topIc
Acute clinical manifestations of severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) infection are less common and less severe in children than in 
adults
Recent observations, however, have raised concerns about a paediatric 
inflammatory multisystem syndrome temporally associated with SARS-CoV-2 
infection (PIMS-TS), with shock, cardiac, respiratory, renal, gastrointestinal, or 
neurological disorders
WhAt thIs study Adds
Kawasaki-like multisystem inflammatory syndrome temporally associated 
with SARS-CoV-2 infection has characteristics that differ from those of classic 
Kawasaki disease
The characteristics comprise a higher frequency in children of African ancestry, 
predominant acute gastrointestinal symptoms, haemodynamic instability, and 
myocarditis
These clinical findings should prompt high vigilance among primary care and 
emergency doctors, and preparedness during the coronavirus disease 2019 
pandemic in countries with a high proportion of children of African ancestry and 
high levels of community transmission
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form of Kawasaki disease, is often associated with 
myocarditis and requires critical care support during 
the acute phase of illness.8 9 Although the cause of 
Kawasaki disease remains unclear, the role of a viral 
trigger in some genetically predisposed children has 
been hypothesised, as several viral respiratory agents 
have been associated with Kawasaki disease,10-12 
including seasonal coronavirus in some studies,13 14 
although not all studies.15 16
Recently, 17 children with signs and symptoms 
consistent with Kawasaki disease and laboratory 
evidence of recent SARS-CoV-2 infection were 
reported in the United States (n=1), England (n=8), 
and Italy (n=8).17-19 These reports included cases 
with hyperinflammatory syndrome and multiorgan 
involvement, provisionally named paediatric inflam-
matory multisystem syndrome temporally associated 
with SARS-CoV-2 infection (PIMS-TS) in Europe20 
and multisystem inflammatory syndrome in children 
(MIS-C) in the United States.21 Given the highly 
variable prevalence of SARS-CoV-2 infection in Europe, 
the possibility of an association between Kawasaki 
disease and positive testing for SARS-CoV-2 needs 
confirmation.
We evaluated a potential temporal association with 
SARS-CoV-2 infection in a cluster of 21 children and 
adolescents with features of Kawasaki disease who 
were admitted to the general paediatric department of 
a university hospital in Paris, France between 27 April 
and 11 May 2020 and followed up until discharge by 
15 May.
Methods
We included all children and adolescents (aged ≤18 
years) who were admitted to the general paediatric 
department of Necker Hospital for Sick Children in 
Paris, France between 27 April and 11 May 2020 and 
met the criteria for Kawasaki disease.7 Patients were 
followed up until discharge by 15 May 2020. This 
university hospital serves as the regional reference 
centre for emerging infectious diseases in children. All 
parents provided written informed consent.
We reviewed the medical files of all the patients 
to collect personal and clinical data, laboratory test 
results, and imaging and echocardiographic findings 
using a standardised study specific form. For the 
purposes of this study, we used the criteria of the 
American Heart Association to define the presence 
of complete and incomplete Kawasaki disease,7 and 
the criteria proposed by Kanegaye et al to define 
Kawasaki disease shock syndrome.8 From each patient 
we obtained at least two nasopharyngeal swabs to 
test for SARS-CoV-2 using reverse transcription-
polymerase chain reaction (RT-PCR; SARS-CoV-2 
R-GENE, Argene; bioMerieux, Marcy l’Étoile, France). 
To exclude hospital acquired SARS-CoV-2 infection, 
we collected samples from the patients for RT-
PCR testing within the first three days of hospital 
admission. We also took blood samples to test for IgG 
antibodies against SARS-CoV-2 (Architect SARS-CoV-2 
chemiluminescent microparticle immunoassay -CMIA-; 
Abbott Core Laboratory, IL),22 and other laboratory 
tests, such as for inflammatory and cardiac markers. 
Standard cardiology investigations included regular 
electrocardiography and echocardiography. We defined 
a coronary artery dilation to be present if the coronary 
artery diameter z score was between 2.0 and <2.5 and 
an aneurysm to be present if the z score was 2.5 or 
greater.7 Resistance to intravenous immunoglobulin 
treatment was defined as persistent or recrudescent 
fever at least 36 hours and less than seven days after 
completion of the first immunoglobulin infusion.7
We described patients’ characteristics using 
medians and percentages. Differences between groups 
were assessed by the Mann-Whitney U test. Statistical 
analysis was carried out using SPSS v25 (SPSS, 
Chicago, IL).
Patient and public involvement
We acknowledge the importance of public involvement. 
For this study, limited staff resources and absence 
of dedicated funding, short delays, and lockdown 
challenges made involving patients and members of 
the public, and especially children and adolescents, 
not possible at this time. We did make sure our 
participants remained aware of the progress of the 
ongoing study and its aims.
results
evidence of sars-cov-2 infection
Between 27 April and 11 May 2020, a total of 21 
children and adolescents were admitted with features 
of Kawasaki disease (table 1). In response to the 
covid-19 pandemic, France closed schools and began 
its lockdown on 17 March 2020. According to the 
parents, all 21 patients reported here had not left 
home for school, social gatherings, or travel since 
lockdown was implemented. A recent history of viral-
like symptoms was reported in nine of the patients: 
headache, cough, coryza, fever for less than 48 
hours, and, for one patient, anosmia. The median 
duration between these symptoms and the onset 
of signs and symptoms of Kawasaki disease was 45 
(range 18-79) days. A history of recent contact with 
family members displaying viral-like symptoms was 
reported in 10 households: parents or grandparents 
(n=11) and siblings (n=3). Symptoms in five of these 
family contacts were highly suspicious of covid-19 
(ageusia, anosmia, suggestive findings on thoracic 
computed tomography). One contact had a positive 
RT-PCR test result for SARS-CoV-2 while symptoms 
were still present. The median interval between 
the reported contact and Kawasaki disease was 36 
(range 18-45) days. The result of RT-PCR testing for 
SARS-CoV-2 was positive in eight (38%) of the 21 
patients presented here (table 2). All but one of them 
had no symptoms suggestive of covid-19; one had 
anosmia that started 24 hours before the symptoms 
of Kawasaki disease. IgG antibodies against SARS-
CoV-2 were detected in 19 of the 21 (90%) patients, 
with a median IgG index of 5.4 (range 2-9). The two 
patients with negative IgG results also tested negative 
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for SARS-CoV-2 by RT-PCR. These two patients with 
complete and incomplete Kawasaki disease according 
to the American Heart Association criteria7 had no 
myocarditis and did not require intensive care support. 
Their procalcitonin levels were less than 1μg/L, and 
coronary artery dilation was detected in one patient. 
Multiplex PCR targeting human respiratory syncytial 
viruses, seasonal coronaviruses, parainfluenza and 
influenza viruses, metapneumovirus, and rhinovirus/
enterovirus in nasopharyngeal swabs, was negative in 
19 patients tested; serum PCR results for adenovirus, 
Epstein Barr virus, cytomegalovirus, human her-
pesvirus 6, and parvovirus B19 were negative in nine 
patients tested, and one patient with positive anti-
SARS-CoV-2 IgG also had a serology suggestive of 
recent Epstein Barr virus infection.
clinical features
Table 1 presents the clinical features of the 21 patients 
admitted with a diagnosis of Kawasaki disease. The 
ratio of male patients to female patients was 0.75. The 
median age at presentation was 7.9 (range 3.7-16.6) 
years. Twelve (57%) patients had at least one parent 
originating from sub-Saharan Africa or a Caribbean 
island, and three (14%) from Asia (two from China, 
one from Sri Lanka). The 21 patients had no relevant 
personal or family medical history, and none reported 
living in unhealthy environments or social housing. 
Sixteen (76%) patients had a body mass index below 
the 97th centile.
Eleven (52%) of the patients fulfilled the complete 
criteria for Kawasaki disease, whereas the remaining 
10 had incomplete Kawasaki disease. Among the 
principal criteria for Kawasaki disease, polymorphous 
skin rash (76%), changes to the lips and oral cavity 
(76%), and bilateral bulbar conjunctival injection 
(81%) were the most common signs. All the patients 
had gastrointestinal symptoms, which occurred early 
in the course of illness before the onset of the principal 
manifestations of Kawasaki disease and consisting of 
acute abdominal pain, often associated with vomiting 
and diarrhoea (95%). Four patients had peritoneal 
effusion, with acute surgical abdomen in two of the 
four. One of them underwent abdominal surgery for 
suspected appendicitis, but had aseptic peritonitis. 
Irritability was common (57%), and six (29%) patients 
presented with headaches, confusion, or meningeal 
irritation. One of the three patients who underwent 
lumbar puncture had cerebrospinal fluid pleocytosis. 
Among other acute manifestations of Kawasaki 
disease, pericardial effusions occurred in 10 (48%) 
patients and pleural effusion in three (14%) patients. 
Myocarditis was diagnosed in 16 (76%) patients, with 
left ventricular ejection fraction ranging between 10% 
and 57%. Two of these 16 patients displayed important 
electrocardiographic changes (increased QT interval 
and occasional ventricular arrhythmias or diffuse ST-
segment elevation) not attributable to any drug for QTc 
prolongation.
imaging and laboratory findings
Of the 18 patients who underwent chest imaging 
(radiography or computed tomography), ground glass 
opacities, local patchy shadowing, and interstitial 
abnormalities were present in eight (44%) patients 
(table 2). Echocardiography detected coronary artery 
abnormalities in eight (38%) patients after a median 
of 7.5 (range 5-11) days of fever, which consisted 
of dilations (z score between 2.0 and 2.5) in five 
(24%) patients and increased coronary visibility in 
three (14%) patients. No coronary aneurysms were 
identified.
All patients had high levels of inflammatory 
markers, including leucocytosis with a predominance 
of neutrophils, and high levels of C reactive protein, 
procalcitonin, and serum interleukin 6 (IL-6; table 
2). Seventeen (81%) patients had lymphopaenia, and 
anaemia was common, with a median haemoglobin 
level of 86 (range 53-122) g/L. Hyponatraemia 
(<135 mmol/L) and hypoalbuminaemia (<32 g/L) 
were observed in 20 (95%) patients. Transient 
kidney failure was observed in 11 (52%) patients. 
Moderate increases in serum alanine transaminases 
and γ-glutamyltransferase levels occurred in 62% 
and 76% of patients, respectively, and increases in 
γ-glutamyltransferase occurred after a median of 6.5 
(range 5-16) days after disease onset. Lipase was 
increased in 10/16 (63%) patients tested. D-dimer 
levels were increased (>500 μg/L) in 19/20 (95%) 
patients. Increased levels of high sensitivity cardiac 
troponin I (>26 pg/mL) and B-type natriuretic peptide 
(>100 ng/L) were found in 17/21 (81%) and 14/18 
(78%) patients, respectively.
table 1 | clinical characteristics of children and adolescents presenting with symptoms 
and signs of Kawasaki disease during the coronavirus disease 2019 pandemic. values 
are numbers (percentages) unless stated otherwise
characteristics total (n=21)
Personal:
 Median (range) age (years) 7.9 (3.7-16.6)
 Girls 12 (57)
Parents country of birth (n=42):
 Sub-Saharan Africa/Caribbean islands 24 (57)
 Asia 4 (10)
 Europe 12 (29)
 Middle East 2 (5)
Kawasaki disease principal clinical criteria:
 Complete presentation (fever >4 days and ≥4 principal criteria) 11 (52)
 Lips and oral cavity changes 16 (76)
 Bilateral bulbar conjunctival injection 17 (81)
 Rash 16 (76)
 Changes to extremities 10 (48)
 Cervical lymphadenopathy 12 (57)
Median (range) days of fever before intravenous immunoglobulin 5 (0-12)
Kawasaki disease associated clinical features:
 Gastrointestinal symptoms 21 (100)
 Perineal or face desquamation 4 (19)
 Arthralgia 2 (10)
 Irritability 12 (57)
 Other neurological features 6 (29)
 Myocarditis 16 (76)
  Median (range) left ventricular ejection fraction rate 42 (10-57)
 Serous effusion 12 (57)
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treatment and outcomes
All 21 patients received high dose intravenous 
immunoglobulin (2 g/kg) after fever for a median 
duration of 5 (range 0-12) days and low dose aspirin 
(3-5 mg/kg/day) (table 3), and seven patients received 
concomitant corticosteroids (2-10 mg/kg/day). Five 
(24%) patients showed resistance to intravenous 
immunoglobulin and were treated with a second 
infusion (2 g/kg), with corticosteroids (2 mg/kg/day) in 
four of these patients. Eighteen (86%) patients received 
empirical broad spectrum antibiotic treatment, which 
always included a third generation cephalosporin. 
Median duration of antibiotic treatment was 6.5 
(range 2-13) days. All test results for bacteria (urine, 
cerebrospinal fluid, and blood culture) were negative.
Seventeen (81%) patients were admitted to 
an intensive care unit (ICU) for management of 
haemodynamic instability. After hospital admission 
for a median 2 (range 1-5) days, 10 of these patients 
were admitted to the ICU. All presented with the criteria 
for Kawasaki disease on admission to the ICU. Twelve 
(57%) patients were considered to have Kawasaki 
disease shock syndrome: 11 received intravenous 
fluid resuscitation, and eight received vasoactive 
agents because of sustained hypotensive shock. 
Fourteen (67%) patients received inotropic agents for 
myocarditis with cardiac dysfunction. Median duration 
of vasoactive or inotropic agents was 3 (range 1-7) days. 
Eleven (52%) patients needed mechanical ventilation 
for cardiovascular compromise. Patients admitted to 
the ICU had higher levels of systemic inflammation 
markers, with a higher peak procalcitonin level 
(26 μg/L, range 1.7-448 μg/L), compared with those 
who did not require admission to the ICU (1 μg/L, 
range 0.13-4.17 μg/L; P=0.001). Median ICU length of 
stay was 5 (range 3-15) days. By 15 May 2020, after 
8 (range 5-17) days of hospital stay, all patients were 
discharged home. No deaths were recorded.
discussion
In this study, the temporal association between the 
onset of the covid-19 pandemic in France and the 
results of tests (RT-PCR and IgG antibodies) for SARS-
CoV-2 in our patients with Kawasaki-like disease 
suggests a causal link. Furthermore, only one patient 
had symptoms suggestive of acute covid-19 and most 
had positive serum test results for IgG antibodies, 
suggesting that the development of Kawasaki disease 
in these patients is more likely to be the result of a post-
viral immunological reaction. An association between 
Kawasaki disease and viral respiratory infections 
has been suspected,10 14 23 especially rhinovirus and 
enterovirus, and various viral agents, including human 
coronaviruses.10 13 14 However, no difference has been 
reported in clinical presentation between patients 
with Kawasaki disease with and without documented 
respiratory viral infection.10
In our series, we describe a Kawasaki-like multi-
system inflammatory syndrome with an over-
representation of myocarditis and Kawasaki disease 
shock syndrome, consistent with recent findings.18 
19 Mild myocarditis is common in the early phase of 
Kawasaki disease, as shown by cardiac biopsies and 
scintigraphy,24 25 and generally improves quickly as 
inflammation resolves.24 26 More severe myocarditis 
with decreased left ventricular contractility can 
sometimes occur, however, especially in the context 
of Kawasaki disease shock syndrome. This syndrome 
is a rare complication that affects 1.5% to 7.0% of 
patients with Kawasaki disease, and it has a higher 
incidence in Western countries compared with Asian 
countries.9 It results from both myocardial dysfunction 
and decreased peripheral vascular resistance, usually 
requiring intravenous fluid resuscitation together with 
inotropic and vasoactive agent infusion in ICU.8  27 
Kawasaki disease shock syndrome might mimick toxic 
shock syndrome,8 justifying systematic antibiotic 
use in our series. The pathophysiology of Kawasaki 
disease shock syndrome remains unclear. A high 
level of circulating pro-inflammatory cytokines might 
contribute to the distributive component of shock. 
Indeed, Kawasaki disease shock syndrome has been 
found associated with high levels of IL-6, C reactive 
protein, and procalicitonin.9 In our series, we observed 
high levels of procalcitonin; 10-fold higher than those 
recently reported in 27 patients with Kawasaki disease 
table 2 | imaging and laboratory findings of children and adolescents presenting 
with symptoms and signs of Kawasaki disease during the coronavirus disease 2019 
pandemic. values are medians (ranges) unless stated otherwise
characteristics total (n=21)
Ultrasound findings on coronary arteries during hospital admission (No (%)):
 Increased visibility 3 (14)
 Dilation (z score 2 to <2.5) 5 (24)
 Aneurysm (z score ≥2.5) 0
Chest radiography or computed tomography abnormalities (No (%)):
 Ground glass opacity, local patchy shadowing, interstitial abnormalities 8/18 (44)
Biochemistry findings:
 White cell count (×109/L) 17.4 (5.4-42.8)
 Neutrophil count (×109/L) 13.6 (3.3-36.4)
 Lymphocyte count (×109/L) 1.1 (0.4-5.6)
 Haemoglobin (g/L) 86 (53-122)
 Platelet count (×109/L) 499 (78-838)
 C reactive protein (mg/L) 253 (89-363)
 Procalcitonin (μg/L) 22.5 (0.1-448)
 Interleukin 6 (pg/mL)* 170 (4-1366)
 Sterile pyuria (No (%))† 10/16 (63)
 Albumin (g/L) 21 (16-37)
 Natrium (mmol/L) 130 (116-135)
 Creatinine (μmol/L) 63 (27-417)
 Alanine aminotransferase (IU/L) 70 (6-257)
 γ-glutamyl transferase (IU/L) 59 (10-205)
 Lipase (IU/L)† 108 (19-537)
 Lactates (mmol/L)* 2.8 (1.6-9)
 D-dimers (μg/L)‡ 4025 (350-19330)
 High sensitivity cardiac troponin I (ng/L) 282 (10-6900)
 B-type natriuretic peptide (ng/L)§ 3354 (16-16017)
Positive microbiological findings:
 Nasopharyngeal SARS-CoV-2 RT-PCR 8 (38)
 Positive SARS-CoV-2 serum serology (IgG)‡ 19 (90)
 Positive nasopharyngeal PCR for other viruses 0/19
RT-PCR=reverse transcription-polymerase chain reaction; PCR=polymerase chain reaction; SARS-CoV-2=severe 
acute respiratory syndrome coronavirus 2; IgG=immunoglobulin G.
*Missing data for four patients.
†Missing data for five patients.
‡Missing data for one patients.
§Missing data for three patients.
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shock syndrome.9 C reactive protein and IL-6 levels 
were also high. This major pro-inflammatory state, 
together with multiorgan dysfunction, recently named 
paediatric inflammatory multisystem syndrome 
temporally associated with SARS-CoV-2 infection 
(PIMS-TS),20 might reflect a particularly strong post-
viral immunological reaction to SARS-CoV-2 compared 
with other viral agents.28 Of note, a cytokine storm 
syndrome with increased levels of inflammatory 
markers such as IL-6 was described in adults with 
covid-19,29 and it has been associated with fatality.30
Besides inflammatory markers, clinical and bio-
logical features of our patients were often consistent 
with the diagnosis of Kawasaki disease shock 
syndrome. Indeed, older age, higher D-dimer levels, 
lower haemoglobin and albumin levels, and more 
severe hyponatraemia were previously found to be 
associated with Kawasaki disease shock syndrome.9 
In contrast with a recent series,18 only 24% of our 
patients had a body mass index above the 75th centile, 
which does not support the hypothesis of overweight 
as a risk factor for Kawasaki-like multisystem 
inflammatory syndrome temporally associated with 
SARS-CoV-2 infection. Resistance to intravenous 
immunoglobulin treatment and coronary artery 
abnormalities were less common in our series than in 
previous series of Kawasaki disease shock syndrome.8 
9 However, these results should be treated with 
caution as coronary artery abnormalities might appear 
later during follow-up. Gastrointestinal symptoms 
were also unusually common, affecting all of our 21 
patients. A previous study reported intestinal pseudo-
obstruction in only 2% of 310 patients with Kawasaki 
disease.31 As previously described, other symptoms of 
Kawasaki disease appeared after the intestinal ones 
in all patients, which could have led to diagnostic 
and therapeutic delays in some children.32 Suspected 
mechanisms involve intestinal ischaemia secondary to 
bowel vessel vasculitis. Rapid resolution of symptoms 
in all patients after treatment with intravenous 
immunoglobulin supports this hypothesis.
The observation of a higher proportion of patients 
of African ancestry is consistent with recent 
findings,18 suggesting an effect of either social and 
living conditions or genetic susceptibility. Kawasaki 
disease is rarely reported in sub-Saharan Africa, but 
it might be more common than previously thought.33 
In the United Kingdom and the United States, a 2.5-
fold higher incidence was reported in children of 
Asian ancestry than of European ancestry, with an 
intermediary 1.5-fold risk for children of African 
ancestry.34 35 Besides, African-Americans have been 
disproportionately affected by the covid-19 pandemic, 
also suggesting an increased susceptibility to severe 
SARS-CoV-2 infection.36 37 Therefore, African countries 
where the SARS-CoV-2 pandemic has spread might 
face a potentially large number of children with 
Kawasaki disease, and supply shortages of intravenous 
immunoglobulin should be anticipated in such 
settings. The absence of reported cases of Kawasaki-
like multisystem inflammatory syndrome associated 
with SARS-CoV-2 infection in Asian countries where the 
covid-19 pandemic started, and where the incidence of 
Kawasaki disease is the highest, is noteworthy.38 Ethnic 
differences in the development of Kawasaki disease 
shock syndrome were previously reported, with a 
lower incidence in Asian countries than in Western 
countries.89 This warrants future studies investigating 
underlying genetic and immunological mechanisms.
table 3 | treatment and outcomes of children and adolescents presenting with 
symptoms and signs of Kawasaki disease during the coronavirus disease 2019 
pandemic. values are numbers (percentages) unless stated otherwise
variables total
Treatment:
 Intravenous immunoglobulin (2g/kg) infusion 21 (100)
 Intravenous immunoglobulin (2g/kg) retreatment 5 (24)
 Steroids (2-10 mg/kg/day) 10 (48)
 Aspirin (3-5 mg/kg/day) 21 (100)
 Broad spectrum antibiotics 18 (86)
Outcome and serious complications:
 Persistent fever 36 hours after end of initial intravenous infusion 5 (24)
 Median (range) length of hospital stay (days) 8 (5-17)
 Admitted to intensive care unit 17 (81)
 Fluid resuscitation 11 (52)
 Vasoactive and inotropic agents* 15 (71)
 Mechanical ventilation 11 (52)
 Death 0
*Adrenaline, dobutamine, milrinone and/or noradrenaline.
table 4 | Main features of classic Kawasaki disease and Kawasaki-like multisystem inflammatory syndrome. numbers 
are percentages of people affected unless stated otherwise
characteristics classic Kawasaki disease* Kawasaki-like syndrome series
High risk population Asian African
Age 6 months-5 years 4-17 years
Incomplete form of Kawasaki disease† 5-20 48
Gastrointestinal symptoms Uncommon 100
Kawasaki disease shock syndrome 2-7 57
Myocarditis with ventricular dysfunction <1 76
Intensive care support 4 81
Levels of inflammatory markers Increased Noticeably increased
Lymphopaenia Rare 81
Coronary artery dilations/aneurysm 4-13 24
Intravenous immunoglobulin resistance 10-20 24
*Supported by Li et al,9 Saundankar et al,40 Makino et al,6 and McCrindle et al.7
†Incomplete form according to American Heart Association criteria7: fever ≥5 days, 2 or 3 principal clinical criteria of Kawasaki disease, and 
echocardiographic or laboratory features of Kawasaki disease.
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limitations of this study
Our study has limitations. Firstly, potential recruitment 
bias might have contributed to the high number of 
patients with Kawasaki-like multisystem inflammatory 
syndrome admitted to the general paediatric depart-
ment in our hospital. This hospital is the referral 
centre for paediatric patients with severe covid-19 in 
the Paris area. Secondly, the low number of patients 
precluded indepth comparisons of phenotypes with 
adequate statistical power. Thirdly, a causal link 
with SARS-CoV-2 infection has not been established, 
despite a strong suspicion of exposure to SARS-CoV-2. 
Household members were not systematically tested 
for SARS-CoV-2 ongoing infection. Besides, a new 
released kit for antibody testing has been used and 
false positive results for SARS-CoV-2 IgG assay might 
occur as a result of cross reactivity from pre-existing 
antibodies.39 However, a study recently reported 
99.9% specificity and 100% sensitivity for this assay.22 
Also, since Kawasaki-like multisystem inflammatory 
syndrome might induce immune reactions with 
multiple antibody production, patients may show 
transient cross reactive IgG leading to false positive 
serology results for SARS-CoV-2. IgG antibody levels 
against SARS-CoV-2 should therefore be monitored.
conclusions and policy implications
Our study documents an outbreak of Kawasaki-like 
multisystem inflammatory syndrome in children and 
adolescents in the Paris area and its association with 
recent SARS-CoV-2 infection. Further studies are 
needed to explore potential causality. The patients 
reported here had characteristics that differ from those 
of patients with classic Kawasaki disease (table 4): 
this present form seems to be more common among 
children of African ancestry, with predominant acute 
gastrointestinal symptoms, haemodynamic instability, 
and myocarditis. These clinical findings should 
prompt high vigilance among primary care and 
emergency doctors, and preparedness during the 
covid-19 pandemic in countries with a high proportion 
of children of African ancestry.
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